Cambridge, United States
Aera Therapeutics, founded in 2021, is a pioneering entity in the Biotechnology and Pharmaceutical industries. Headquartered in the United States, the company's slogan, "Enabling the next generation of transformative genetic medicines," accurately encapsulates its mission.
The firm aims to address a critical challenge in genetic medicine—delivery mechanisms. Leveraging innovative technological platforms like targeted lipid nanoparticles (tLNPs), antibody oligonucleotide conjugates (AOCs), and protein nanoparticles (PNPs), Aera Therapeutics seeks to revolutionize the way genetic medicines are delivered for various therapeutic modalities and disease areas.
In a promising advancement, Aera secured a $58.00M Series B investment on 01 February 2023, backed by reputable investors such as Lux Capital, Arch Venture Partners, and GV. This financial endorsement underscores strong market confidence and positions Aera for significant growth and innovation in the genetic medicine landscape.
ReCode Therapeutics